The organisation – which has been listed as a 501 (c) non-profit organisation by the US Internal Revenue Services (IRS) for over a decade - explained how the new charitable status will impact operations.
“Just one of the benefits of this new status is the ability to receive tax-deductible contributions from individual and corporate donors. This will assist in promoting CDISC’s message to a broader audience, enhancing CDISC’s capacity to locate funds through diverse means.
“CDISC has always been exempt from paying federal corporate income tax, but will now no longer be required to pay sales tax; this will allow for these funds to be put toward CDISC’s strategic goals, which include the development of global disease-specific research standards to benefit patients around the world.”
Organisation executive VP of finance and administration Shirley Williams also suggested CDISC’s new status would be beneficial for the various organisations it works with
"With our new status, individual and corporate contributions to CDISC not only will further our mission and help patients on a global scale, but will now also further assist our donors through the provision of tax deductions on their contributions,"
CDISC standards are used by the contract research sector as well as a number of public-private groups, including the joint EU European Federation of Pharmaceutical Industries and Associations’ (EFPIA) Innovative Medicines Initiative (IM) which adopted them last month .